Associations - RET (Ret Proto-Oncogene)

RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET fusion	Thyroid Gland Carcinoma	RET fusion	Thyroid Gland Carcinoma	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET mutation	Thyroid Gland Medullary Carcinoma	RET mutation	Thyroid Gland Medullary Carcinoma	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1	pralsetinib Sensitive: A1 - Approval pralsetinib Sensitive : A1
RET fusion	Solid Tumor	RET fusion	Solid Tumor	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1	selpercatinib Sensitive: A1 - Approval selpercatinib Sensitive : A1
RET fusion	Thyroid Gland Hurthle Cell Carcinoma	RET fusion	Thyroid Gland Hurthle Cell Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Thyroid Gland Follicular Carcinoma	RET fusion	Thyroid Gland Follicular Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2	cabozantinib tablet Sensitive: A2 - Guideline cabozantinib tablet Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET rearrangement	Non Small Cell Lung Cancer	RET rearrangement	Non Small Cell Lung Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET mutation	Thyroid Gland Anaplastic Carcinoma	RET mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET M918T	Thyroid Gland Medullary Carcinoma	RET M918T	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2	cabozantinib capsule Sensitive: A2 - Guideline cabozantinib capsule Sensitive : A2
RET fusion	Non Small Cell Lung Cancer	RET fusion	Non Small Cell Lung Cancer	vandetanib Sensitive: A2 - Guideline vandetanib Sensitive : A2	vandetanib Sensitive: A2 - Guideline vandetanib Sensitive : A2
RET fusion	Thyroid Gland Papillary Carcinoma	RET fusion	Thyroid Gland Papillary Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Hurthle Cell Carcinoma	RET fusion	Thyroid Gland Hurthle Cell Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Follicular Carcinoma	RET fusion	Thyroid Gland Follicular Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Thyroid Gland Anaplastic Carcinoma	RET fusion	Thyroid Gland Anaplastic Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Neuroendocrine Tumor	RET fusion	Neuroendocrine Tumor	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Ovarian Cancer	RET fusion	Ovarian Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Salivary Gland Cancer	RET fusion	Salivary Gland Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Colon Cancer	RET fusion	Colon Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Biliary Tract Cancer	RET fusion	Biliary Tract Cancer	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
RET fusion	Hepatocellular Cancer	RET fusion	Hepatocellular Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Colorectal Cancer	RET fusion	Colorectal Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Pancreatic Adenocarcinoma	RET fusion	Pancreatic Adenocarcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Biliary Tract Cancer	RET fusion	Biliary Tract Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Peritoneal Cancer	RET fusion	Peritoneal Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Fallopian Tube Cancer	RET fusion	Fallopian Tube Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
RET fusion	Cervical Cancer	RET fusion	Cervical Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2

RET (Ret Proto-Oncogene)

Associations(253)

Associations
(253)